Medidata Solutions offers cloud-based solutions for managing clinical trials in the life sciences industry, serving pharmaceutical, biotech, and medical device companies, as well as academic institutions. Their main products include Rave EDC for electronic data capture, eCOA for electronic clinical outcome assessments, and ePRO for electronic patient-reported outcomes, all designed to enhance the efficiency and accuracy of clinical trials. Medidata differentiates itself from competitors by combining advanced technology with deep data insights, helping clients bring new treatments to market more quickly and cost-effectively. The company's goal is to improve patient outcomes through effective clinical trials while promoting diversity and inclusion.

Insight Partners

Dassault Systemes

US Department of Defense

Enterprise Software

Biotechnology

Healthcare

Medidata Solutions

AVIZVA, a health-tech organization that offers a variety of solutions for healthcare enterprises, that it has appoints James Vertino as its new CEO.Model N appoints Bret Connor as Chief Executive Officer. The Board of Directors of Blue Shield of California appoints Lois Quam as chief executive officer to lead Blue Shield of California, the first woman to serve as CEO in the health plan’s 86-year history. She joined the company as president in 2024.   Yaqrit, a late-stage biotech and medtech company developing lifesaving treatments for advanced liver diseases appoints Troels Jordansen has joined Yaqrit as Chief Executive Officer.OP Solutions names Michael Kallish as Chief Executive Officer, effective immediately.Access TeleCare appoints Dr. Michael Genovese to Chief Medical Officer for Behavioral Health.Enveda appoints Jason Kim as Chief Financial Officer (CFO).Eko Health appoints of Justin Spencer as Chief Financial Officer (CFO). (Pull from site)Qure.ai appoints Jim Mercadante as its new Chief Commercial Officer. (Pull from site)Symplr, appoints Dr

Recent Digital Health Executive Hires And Promotions: Medidata Expands Team, Carerev, Philips, Eko Health, Others

Medidata Platform Enhances Clinical Trial Efficiency for Bristol Myers Squibb. by Syed Hamza Sohail 01/08/2025 Leave a Comment. What You Should Know:– Medidata, a Dassault Systèmes brand and a leader in clinical trial solutions for the life sciences industry, has announced an extended and expanded partnership with Bristol Myers Squibb (BMS).–  This collaboration aims to enhance clinical research processes, improve patient outcomes, and foster advancements in personalized healthcare. Medidata and Bristol Myers Squibb Strengthen Partnership to Advance Clinical Research and Personalized Healthcare As part of the agreement, Bristol Myers Squibb will continue utilizing the Medidata Platform while exploring additional capabilities within Medidata’s suite of products. These include: – AI and advanced analytics to derive deeper insights from clinical trial data. – Innovative data management solutions to streamline trial operations. – The Medidata Clinical Data Studio, a newly launched tool designed to manage, monitor, and analyze clinical trials effectively. This strategic partnership extension will enable Bristol Myers Squibb to strengthen engagement with trial sites and patients, optimize processes, and accelerate the delivery of life-changing therapies to those in need. By leveraging cutting-edge technology, both organizations aim to set new benchmarks in clinical research and personalized treatment development

Medidata Platform Enhances Clinical Trial Efficiency For Bristol Myers Squibb

Meghan Harrison, VP of Clinical Trial Financial Management at MedidataAchieving diversity in clinical trials is crucial for developing effective and safe treatments for all populations. Yet, financial barriers often exclude underrepresented groups from participating, hindering progress towards health equity. This disparity raises critical questions about the accessibility and inclusivity of medical research.In this insightful QA, Meghan Harrison, VP of Clinical Trial Financial Management at Medidata, a Dassault Systèmes brand, sheds light on the financial challenges hindering diversity in clinical trials. She explores how financial constraints, such as limited banking access and tax implications, disproportionately affect underrepresented patients. Furthermore, she delves into the cash flow issues plaguing trial sites and discusses how innovative platforms are addressing these challenges to promote greater inclusivity in medical research.What policy changes or regulatory adjustments are needed to address the financial barriers faced by patients and trial sites? Meghan Harrington, VP of Clinical Trial Financial Management at Medidata: There is a growing body of literature on the financial toxicity of healthcare that details the patient financial burdens related to the cost of medical care. This research has recently turned to the clinical trial experience

Q/A: Medidata Vp Talks Overcoming Financial Barriers To Diversity In Clinical Trials

What You Should Know:– Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced the launch of Medidata Patient Payments, a new solution that streamlines trial-related stipends and reimbursements for patients participating in clinical research.– This offering automates the payment lifecycle and addresses the longstanding challenge of compensating participants for their time, effort, and study-related expenses, while solving for growing concerns around the financial toxicity of clinical trial encounters.Medidata: Transforming Clinical Trials with Innovative Digital SolutionsCelebrating 25 years of technological innovation, Medidata leads the way in revolutionizing clinical trials through its comprehensive digital platform. With expertise built from over 34,000 trials and data from more than 10 million patients, Medidata offers cutting-edge analytics, the world’s largest patient-level historical clinical trial dataset, and industry-leading solutions. Trusted by more than 1 million registered users across approximately 2,200 customers, Medidata’s seamless, end-to-end platform accelerates clinical breakthroughs, improves patient experiences, and helps bring therapies to market more efficiently.Medidata Patient Payments delivers a streamlined reimbursement experience for clinical trial participants, allowing for the easy submission of various expense claims, including:– Travel– Meals– Lodging– Lost wages– Childcare– MileageThe platform leverages the Medidata system to automatically trigger stipends based on study-related activities, such as completing diaries or assessments, enhancing both flexibility and convenience. This integrated approach ensures a smooth reimbursement process, with quick implementation and customizable options to suit the needs of both patients and study sites.“Our Patient Payments solution is a direct reflection of the commitment and passion we have to deliver an extraordinary patient experience,” said Meghan Harrington, vice president, Clinical Trial Financial Management, Medidata. “Our partnerships with Medidata’s patient and site advisory boards, coupled with the incomparable data housed within our ecosystem, provides us with a unique opportunity to modernize the financial management experience for patients.”

Medidata Launches Patient Payments: Streamlining Clinical Trial Reimbursements

What You Should Know:–  Cognizant (Nasdaq: CTSH) announced an expanded agreement with Medidata, a Dassault Systèmes brand and leader of clinical trial solutions to the life sciences industry, to provide support for Medidata’s life sciences clients and expand the strategic alliance partnership. –  Over the years, the companies have partnered to deliver a comprehensive framework supporting life sciences clients, emphasizing customer success, patient service desk, implementation, engineering, integrations, and user acceptance testing services using Medidata’s clinical platform and solutions. Cognizant and Medidata: Transforming Clinical Research Through AI-Powered InnovationCognizant (Nasdaq: CTSH) engineers modern businesses by helping clients modernize technology, reimagine processes, and transform experiences to stay ahead in a fast-changing world. In a renewed multi-year collaboration, Cognizant and Medidata aim to enhance responsiveness and improve user satisfaction for life sciences organizations relying on Medidata’s technology services for clinical trial development.·       Dedicated Medidata Platform Support: Cognizant provides a specialized team of Medidata Platform experts to assist pharmaceutical, biotech, medical device, and contract research organizations, as well as patients using Medidata services. This support maximizes Medidata’s value for life sciences clients, improving the overall user experience and enabling clients to focus on clinical trial development and patient outcomes.·       AI-Driven Clinical Trial Acceleration: The partnership expands access to Medidata’s AI-powered technologies, including Medidata Clinical Data Studio, Medidata Health Record Connect, and the myMedidata patient portal. These solutions streamline research and development by enhancing patient, site, and data experiences.·       Operational Excellence and Data Modernization: As a top Global Medidata Strategic Alliance Partner, Cognizant leverages its extensive network of Medidata Certified Services Professionals to help life sciences organizations modernize clinical operations and data management.“Our partnership with Cognizant represents a shared commitment to transforming clinical research through innovation and expertise,” said Janet Butler, EVP, Head of Global Sales, Medidata. “By combining Medidata’s advanced AI-driven technologies with Cognizant’s deep industry knowledge and operational excellence, we support life sciences organizations in streamlining their RD efforts, deriving actionable insights from complex data, and ultimately bringing life-changing therapies to patients more efficiently.”

Medidata And Cognizant Expand Partnership To Accelerate Clinical Trial Development

Collaboration underscores Bristol Myers Squibb’s commitment to unleashing the power of digital technologies to advance its mission to discover, develop, and deliver Innovative medicines that help patients prevail over serious diseasesNew York – Jan. 7, 2025 – Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that it has extended and expanded its partnership with Bristol Myers Squibb to help enhance the company’s clinical research processes, advance patient outcomes, and foster personalized healthcare.Bristol Myers Squibb will continue to leverage the Medidata Platform, and is working with Medidata to evaluate additional components of their suite of products including AI and advanced analytics, innovative data management solutions, and the newly launched Medidata Clinical Data Studio to help manage, monitor, and analyze its clinical trials. This strategic extension will enable Bristol Myers Squibb to deepen engagement with trial sites and patients while streamlining processes and expediting the delivery of life-changing therapies to those in need.“We are honored to continue working with BMS in their efforts to leverage the Medidata Platform and unify more of their clinical trial ecosystem.” said Janet Butler, executive vice president, head of global sales, Medidata. “As the use of AI evolves quickly in our industry, it’s exciting to see leaders like BMS adopt practical and impactful technology beyond EDC to speed research and add efficiency for sites.”About MedidataMedidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 35,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster

Medidata Signs Multi-Year Agreement With Bristol Myers Squibb To Extend Relationship And Continue Company’S Use Of Platform

NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an expansion of its relationship with Worldwide Clinical Trials (“Worldwide”), a full-service global contract research organization (CRO). The agreement will facilitate data-driven decision-making across Worldwide’s entire clinical operations with the implementation of Medidata AI and enable Worldwide to support customers by reducing trial timelines and improving site selection. This new collaboration will catapult Worldwide into the next phase of its data evolution, powered by Medidata’s artificial intelligence solutions and its expansive historical data set, the largest in the industry. “Worldwide will accelerate clinical research and advance the life sciences industry by leveraging site-level granularity and real-time actionable observations provided by Medidata AI’s turnkey solution,” says Tom Doyle, chief technology officer, Medidata

Medidata Selected By Worldwide Clinical Trials To Accelerate Trials And Transform Patient Experience

DASSAULT SYSTEMES acquiert MEDIDATA SOLUTIONS

DASSAULT SYSTEMES acquiert MEDIDATA SOLUTIONS, FUSACQ Buzz

Carol Stafford, Medical Device and Diagnostics Executive, MedidataIn the MedTech sector, small and medium-sized organizations are the primary drivers of innovation, developing new technologies for diagnosing, monitoring, and treating various conditions. Despite their potential to transform patient care and enhance efficiency in healthcare environments, these companies face significant funding challenges. The high costs of development, complex regulatory pathways, and intense market competition create substantial barriers to attracting investors.MedTech entrepreneurs must take a multifaceted approach to securing funding. This includes innovative financing models, strategic partnerships, and leveraging advanced data platforms to overcome the challenges that often stifle MedTech innovation.Impact of MedTech InnovationMedTech innovation is crucial not only for addressing pressing healthcare challenges but also for driving economic growth. The sector aims to enhance medical care and generate high-paying jobs, from research and development to manufacturing. The global medical device market is projected to grow from 518.46 billion in 2023 to 886.80 billion by 2032, with a compound annual growth rate (CAGR) of 6.3%.Key Funding Challenges Facing MedTech InnovatorsSecuring funding is a major obstacle for MedTech startups

Funding Challenges For Innovation In Medtech In 2025

NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, was presented with the inaugural Site Innovation Award for its groundbreaking work in improving efficiency in clinical trials by the Summit for Clinical Ops Executives (SCOPE). Medidata Rave Companion was selected as the winner for its ability to elevate the site experience, enabling sites to spend more time conducting research, caring for patients, and delivering high-quality data to sponsors. This next-generation solution enhances data quality and lowers monitoring costs by making it easier and faster to input information into Medidata Rave EDC from other electronic systems, including electronic health records (EHR). In fact, one clinical trial site reported that data entry was 44 times faster with Rave Companion than doing it manually. “We’re honored to receive the Site Innovation Award and to be recognized by SCOPE,” said Dan Braga, vice president, electronic health record and healthcare solutions, Medidata. “We are inspired to continue innovating in all aspects of clinical trials to enhance the experience for everyone involved, including patients.”

Medidata Wins Inaugural Scope Site Innovation Award For Pioneering Advancements In Site Experience With Leading-Edge Technology

Medidata Launches New AI Solution to Modernize the Data Experience in Clinical Trials. by Syed Hamza Sohail 06/18/2024 Leave a Comment. What You Should Know:–       Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced the launch of Medidata Clinical Data Studio, a unified experience that unlocks the true power of clinical research data.–       This groundbreaking technology gives stakeholders greater control over the quality of data and the ability to deliver safer trials to patients faster. Revolutionizing Clinical Trials with Medidata’s Unified Platform and AI-Powered InsightsBuilt on the industry’s only unified platform, Clinical Data Studio integrates data from both Medidata and non-Medidata sources, accelerating decision-making across the full clinical trial process. It delivers holistic data and risk strategies that connect patients, sites, and sponsors. Through AI, study teams can more effectively identify potential data issues and safety signals, resulting in a more accurate understanding of the patient. This approach reduces the challenges posed by siloed data systems and enables data review and reconciliation up to 80 percent faster. Clinical Data Studio offers a comprehensive workspace for data integration, transformation, and management

Medidata Launches New Ai Solution To Modernize The Data Experience In Clinical Trials

Cloud-based solutions for clinical trials

Medidata Solutions

Cloud-based solutions for clinical trials

Medidata Solutions

Cloud-based solutions for clinical trials

About

Simplify's Take

What believers are saying

What critics are saying

What makes Medidata Solutions unique

Benefits

Recently Posted Jobs

There are no jobs for Medidata Solutions right now.